References
1. Gestational Hypertension and
Preeclampsia: ACOG Practice Bulletin Summary, Number 222.Obstetrics and gynecology 2020; 135 : 1492-5.
2. Abalos E, Cuesta C, Grosso AL et
al. Global and regional estimates of preeclampsia and eclampsia: a
systematic review. European journal of obstetrics, gynecology, and
reproductive biology 2013; 170 : 1-7.
3. Burton GJ, Redman CW, Roberts JM,
Moffett A. Pre-eclampsia: pathophysiology and clinical implications.Bmj 2019; 366 : l2381.
4. Lisonkova S, Joseph KS. Incidence
of preeclampsia: risk factors and outcomes associated with early- versus
late-onset disease. Am J Obstet Gynecol 2013; 209 : 544
e1- e12.
5. Redman CW. Early and late onset
preeclampsia: Two sides of the same coin. Pregnancy Hypertension:
An International Journal of Women’s Cardiovascular Health 2017;7 : 58.
6. Duley L. The global impact of
pre-eclampsia and eclampsia. Seminars in perinatology 2009;33 : 130-7.
7. De Kat AC, Hirst J, Woodward M et
al. Prediction models for preeclampsia: A systematic review.Pregnancy hypertension 2019; 16 : 48-66.
8. Wu L-W, Kao T-W, Lin C-M et al.
Examining the association between serum lactic dehydrogenase and
all-cause mortality in patients with metabolic syndrome: a retrospective
observational study. BMJ Open 2016; 6 : e011186.
9. Qublan HS, Ammarin V, Bataineh O et
al. Lactic dehydrogenase as a biochemical marker of adverse pregnancy
outcome in severe pre-eclampsia. Medical science monitor :
international medical journal of experimental and clinical research2005; 11 : Cr393-7.
10. Certo M, Tsai C-H, Pucino V et
al. Lactate modulation of immune responses in inflammatory versus tumour
microenvironments. Nature Reviews Immunology 2021; 21 :
151-61.
11. Dave A, Maru L, Jain A. LDH
(Lactate Dehydrogenase): A Biochemical Marker for the Prediction of
Adverse Outcomes in Pre-eclampsia and Eclampsia. Journal of
obstetrics and gynaecology of India 2016; 66 : 23-9.
12. Vinitha PM, Chellatamizh M,
Padmanaban S. Role of serum LDH in preeclampsia as a prognostic factor
– a cross sectional case control study in tertiary care hospital.Int J Reprod Contracept Obstet Gynecol 2017; 6 : 595-8.
13. Burwick RM, Rincon M, Beeraka SS
et al. Evaluation of Hemolysis as a Severe Feature of Preeclampsia.Hypertension (Dallas, Tex : 1979) 2018; 72 : 460-5.
14. Liberati A, Altman DG, Tetzlaff J
et al. The PRISMA statement for reporting systematic reviews and
meta-analyses of studies that evaluate health care interventions:
explanation and elaboration. Journal of clinical epidemiology2009; 62 : e1-34.
15. van der Tuuk K, van Pampus MG,
Koopmans CM et al. Prediction of cesarean section risk in women with
gestational hypertension or mild preeclampsia at term. European
journal of obstetrics, gynecology, and reproductive biology 2015;191 : 23-7.
16. Bellos I, Pergialiotis V,
Loutradis D, Daskalakis G. The prognostic role of serum uric acid levels
in preeclampsia: A meta-analysis. The Journal of Clinical
Hypertension 2020; 22 : 826-34.
17. Borenstein M, Hedges LV, Higgins
JPT, Rothstein HR. A basic introduction to fixed-effect and
random-effects models for meta-analysis. Research Synthesis
Methods 2010; 1 : 97-111.
18. IntHout J, Ioannidis JPA, Borm
GF. The Hartung-Knapp-Sidik-Jonkman method for random effects
meta-analysis is straightforward and considerably outperforms the
standard DerSimonian-Laird method. BMC Medical Research
Methodology 2014; 14 : 25.
19. Wan X, Wang W, Liu J, Tong T.
Estimating the sample mean and standard deviation from the sample size,
median, range and/or interquartile range. BMC Medical Research
Methodology 2014; 14 : 135.
20. Duan Z, Li C, Leung WT et al.
Alterations of Several Serum Parameters Are Associated with Preeclampsia
and May Be Potential Markers for the Assessment of PE Severity.Disease Markers 2020; 2020 : 7815214.
21. Khalil MI, Sagr ER, Bahyan R et
al. How accurate are placental growth factor, urate, lactate
dehydrogenase and proteinuria in diagnosing preeclampsia and its
severity? Pregnancy hypertension 2014; 4 : 156-63.
22. Fazal RS, Chandru S, Biswas M.
Evaluation of total LDH and its insoenzymes as markers in preeclampsia.J Med Biochem 2020; 39 : 392-8.
23. Kasraeian M, Asadi N, Vafaei H et
al. Evaluation of serum biomarkers for detection of preeclampsia
severity in pregnant women. Pak J Med Sci 2018; 34 : 1-5.
24. Martin JN, May WL, Magann EF et
al. Early risk assessment of severe preeclampsia: Admission battery of
symptoms and laboratory tests to predict likelihood of subsequent
significant maternal morbidity. American Journal of Obstetrics and
Gynecology 1999; 180 : 1407-14.
25. Gedik E, Yücel N, Sahin T et al.
Hemolysis, elevated liver enzymes, and low platelet syndrome: Outcomes
for patients admitted to intensive care at a tertiary referral hospital.Hypertension in pregnancy 2017; 36 : 21-9.
26. Sibai BM. Imitators of severe
preeclampsia. Obstetrics and gynecology 2007; 109 :
956-66.
27. Keiser SD, Boyd KW, Rehberg JF et
al. A high LDH to AST ratio helps to differentiate pregnancy-associated
thrombotic thrombocytopenic purpura (TTP) from HELLP syndrome. The
journal of maternal-fetal & neonatal medicine : the official journal of
the European Association of Perinatal Medicine, the Federation of Asia
and Oceania Perinatal Societies, the International Society of Perinatal
Obstet 2012; 25 : 1059-63.